自身免疫性肾小球病与足细胞病患者抗利妥昔单抗抗体发生率
研究检测300例接受利妥昔单抗治疗的自身免疫性系统性及肾脏受累疾病患者的1312份血样,54例出现抗药抗体(ADA),且通常与B细胞重建平行。ADA在膜性肾病、系统性红斑狼疮、局灶节段性肾小球硬化等对利妥昔单抗反应较差的诊断中显著更常见,而ANCA相关性血管炎和微小病变中较少。不同疾病ADA形成模式和滴度存在差异。
要点
- 膜性肾病、狼疮、FSGS患者ADA更常见,与利妥昔单抗反应较差相关。
- ANCA相关性血管炎ADA多为低滴度且短暂,膜性肾病滴度更高更持久。
- 不同诊断ADA频率与滴度差异明显,临床意义需按病种分别评估。
核心结论
- ADA形成频率和滴度在不同自身免疫疾病间差异显著,其临床意义应按诊断分别评估。
- 因部分患者即使形成极高滴度ADA仍获良好反应,未能评估ADA对临床反应的干扰。
研究设计与样本
- 研究纳入300例接受利妥昔单抗治疗的自身免疫系统性及肾脏受累疾病患者,检测1312份血样。
- 描述性分析ADA形成频率与滴度。
主要发现
- 54例患者ADA阳性,ADA阳性通常与B细胞重建平行。
- ADA在膜性肾病、系统性红斑狼疮、FSGS及其他少见诊断中较ANCA相关性血管炎和微小病变更常见。
- ANCA相关性血管炎ADA多为低滴度且短暂,膜性肾病滴度更高更持久,FSGS滴度有时高至无法测定且出现较早。
临床怎么用
- 对膜性肾病、狼疮、FSGS等利妥昔单抗反应欠佳病种,可关注ADA形成与B细胞重建情况。
局限性
- 未能评估ADA形成或滴度与临床反应之间的干扰关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-drug antibody (ADA) formation against rituximab (RTX) may affect treatment efficacy, safety, and B-cell depletion kinetics, yet data across different immune-mediated diseases remain limited. We evaluated ADA formation in 1312 blood samples from 300 patients with various autoimmune systemic and kidney-affecting diseases treated by rituximab (RTX) to describe the formation frequency and titers of ADA. ADA positivity was found in 54 patients and typically paralleled B-cell reconstitution. ADAs were significantly more frequent in diagnoses with overall worse response to RTX treatment (membranous nephropathy (MN), systemic lupus erythematosus, focal-segmental glomerulosclerosis (FSGS) and other less frequent diagnoses) compared with standard-response diagnoses (ANCA associated vasculitis (AAV) and minimal change disease). The pattern of ADA formation differed between diagnoses-in AAV ADAs were usually detected in low titers and transiently, in MN ADA titers were higher and more sustained and in FSGS ADA titers were sometimes unmeasurably high and occurred rather early during the treatment. We were not able to evaluate the interference of ADA formation or their titers with clinical response as some of our patients obtained robust response even after formation of unmeasurably high ADA titers. ADA formation frequency and titers markedly differ between different autoimmune diseases, therefore the frequency of their formation and their clinical significance should be evaluated separately in patients with different diagnoses.
引用
- Hartinger JM, Šíma M, Hrušková Z, et al. Prevalence of anti-rituximab antibodies in autoimmune forms of glomerulonephritis and podocytopathies. Nephrol Dial Transplant. 2026. PMID: 42340364. doi:10.1093/ndt/gfag137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。